{"ticker": {"uuid": "e6ddb430-8e7c-4a74-9c44-5a54dbafbc17", "symbol": "SLDB", "name": "Solid Biosciences LLC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Solid Biosciences (SLDB) Proxy filing Summary", "summary": "Solid Biosciences (SLDB) has released its proxy filing summary, detailing proposals for its virtual annual meeting on June 10, 2026. Key items include the election of three Class II directors, ratification of an advisory appointment, approval of the external auditor, and an amend", "url": "https://quartr.com/events/solid-biosciences-inc-sldb-proxy-filing_FkM9LW2d", "source_name": "Quartr", "published_at": "2026-07-16T06:11:14", "published_display": "16 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Solid Biosciences (SLDB) Registration filing Summary", "summary": "This document summarizes Solid Biosciences' (SLDB) registration filing from March 2026, detailing the company's focus on gene therapy for rare neuromuscular and cardiac diseases. It highlights a $240 million private placement, the registration of 42.78 million shares for resale, ", "url": "https://quartr.com/events/solid-biosciences-inc-sldb-registration-filing_FkM9LxPV", "source_name": "Quartr", "published_at": "2026-07-13T10:41:00", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences (SLDB) AGM 2026 Summary", "summary": "This article summarizes Solid Biosciences' (SLDB) 2026 Annual General Meeting (AGM) held on June 12, 2026, as a virtual event. Key outcomes included the election of three Class II directors and the advisory ratification of a Class I director, with a quorum established at 86.57% o", "url": "https://quartr.com/events/solid-biosciences-inc-sldb-agm-2026_FkM9LnAx", "source_name": "Quartr", "published_at": "2026-07-13T01:11:28", "published_display": "13 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices", "summary": "Solid Biosciences Inc. (SLDB) was recently added to several Russell growth indices, including the Russell 2000, 2500, 3000, 3000E, Microcap, and Small Cap Comp Growth indices. This inclusion is expected to increase the company's visibility to institutional investors and index-tra", "url": "https://www.sahmcapital.com/news/content/how-investors-may-respond-to-solid-biosciences-sldb-joining-multiple-russell-growth-indices-2026-07-11", "source_name": "Sahm", "published_at": "2026-07-11T23:11:14", "published_display": "11 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Solid Biosciences (SLDB) Undervalued Following Its Russell Growth Index Additions?", "summary": "Solid Biosciences (SLDB) has been added to several Russell growth indices following a significant share price increase. A Discounted Cash Flow (DCF) model by Simply Wall St suggests the stock is undervalued with a fair value of $140.99 per share compared to its current price of $", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sldb/solid-biosciences/news/is-solid-biosciences-sldb-undervalued-following-its-russell/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T09:10:56", "published_display": "08 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Solid Biosciences LLC For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing by Solid Biosciences LLC for July 7, 2026. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The brief piece indicates that financial markets worldwide can access this information via Inv", "url": "https://ng.investing.com/news/stock-market-news/form-4-solid-biosciences-llc-for-7-july-93CH-2589650", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T21:10:56", "published_display": "07 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Solid Biosciences (SLDB) converts 3,440 RSUs into shares", "summary": "Solid Biosciences Inc. director Ian F. Smith converted 3,440 Restricted Stock Units (RSUs) into common stock on July 2, 2026, at a price of $0.00 per share. This transaction increased his direct holdings to 138,145 shares of Common Stock, with an additional 6,880 RSUs remaining. ", "url": "https://www.stocktitan.net/sec-filings/SLDB/form-4-solid-biosciences-inc-insider-trading-activity-3e9b2deb6698.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:05:53", "published_display": "07 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences updates gene therapy pipeline as investors watch clinical strategy", "summary": "Solid Biosciences, a clinical-stage biotechnology company, is refining its gene therapy focus and clinical strategy for rare neuromuscular and cardiac diseases. The company, which is listed on Nasdaq, is centered on providing long-term treatment options for patients and relies on", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/solid-biosciences-updates-gene-therapy-pipeline-as-investors-watch/69715663", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:40:53", "published_display": "07 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Solid Biosciences' (SLDB) Russell Index Debut Hint at a Turning Point in Its Growth Story?", "summary": "Solid Biosciences Inc. (SLDB) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 3000 Growth. This inclusion is expected to increase institutional visibility and liquidity for the company's stock. While it could broad", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sldb/solid-biosciences/news/does-solid-biosciences-sldb-russell-index-debut-hint-at-a-tu", "source_name": "Simply Wall Street", "published_at": "2026-07-03T07:39:34", "published_display": "03 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences: The Bull Case Is No Longer Just Duchenne", "summary": "Solid Biosciences (SLDB) is transitioning from a Duchenne gene therapy focus to a broader multi-asset rare disease platform, supported by its $380.7M cash position funding operations into 2028. The company's SGT-003 program shows promising Phase 1/2 data for Duchenne, and new pro", "url": "https://seekingalpha.com/article/4919335-solid-biosciences-stock-bull-case-no-longer-just-duchenne", "source_name": "Seeking Alpha", "published_at": "2026-07-02T11:40:10", "published_display": "02 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences stock hits 52-week high at $10.44", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQbHdwempjYWpJNjBUUnJTYllUZmhkUU5tRlJoaTBaTjJNVWpFWTl0d2ZXSHR4dmtIVk9uWmJDQTZ3eTI4Y3d4NnM1a0dydTljR0Zad1lYVEZwdnZjdTR2eDZBZWliRHRjX3dPd3A2d3hEWHFtYUNXeUZiTWd2U0JscUIzbXR4Q05qaFBlcE5DTUdLOXdsbmgwRVNlRjFCT2s3WVN4NDJyNnI?oc=5", "source_name": "Investing.com", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPc2VCdXd5eW9lQjlydGNGeFpERjAzQ3BFbkVNdDBKaHE3eGdaUXlURVQ0SHlfVUF6enhHT0twTW9kNGRvemF3ZmUxcVVYQUUwUzFCWVZPY0ptNTJualhxMEVtdFZnWU5aVTRkbUZWTFRfSUFtcG9LVXFVdVFvcmFZbFdCY1VDS0JYalRNX2ZaeVRFSDlHcHZJaEZKNk9nUmM0ZkE?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2000 Growth Benchmark", "summary": "Solid Biosciences Inc. (NasdaqGS: SLDB), a life sciences company focused on genetic medicines for neuromuscular and cardiac diseases, has been included in the Russell 2000 Growth Benchmark. This addition follows its recent inclusion in the Russell 3000E Growth Benchmark and the S", "url": "https://www.marketscreener.com/news/solid-biosciences-inc-nasdaqgs-sldb-added-to-russell-2000-growth-benchmark-ce7f5fdede81f526", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:14", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Microcap Growth Benchmark Index", "summary": "Solid Biosciences Inc. (SLDB) has been added to the Russell Microcap Growth Benchmark Index, as reported on June 28, 2026. This inclusion highlights the company's progress and visibility within the biotechnology and medical research sector. Solid Biosciences specializes in develo", "url": "https://www.marketscreener.com/news/solid-biosciences-inc-nasdaqgs-sldb-added-to-russell-microcap-growth-benchmark-index-ce7f5fddd981f220", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:10:07", "published_display": "29 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Solid Biosciences Inc. \u2013 NASDAQ:SLDB", "summary": "This article provides financial information for Solid Biosciences Inc. (NASDAQ: SLDB), specifically focusing on its forward price-to-sales ratio. The content lists the company's financial overview within the context of the biotechnology sector.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:40:54", "published_display": "28 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Solid Biosciences Inc. \u2013 NASDAQ:SLDB", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNdTZWUEtYU3VIcHZOSWFRc3o1ZXpjVG9NdkkwbDVLaTFNQjhZcF9lWmt4UnVHSl8wREtwM3phYkcyTHlKeWp3dDdnOXRjQXk0QmlONjhOa29MdVMtSVB5R09aWkozdUNBZ25SWHpaaVZpRTZjQXRMWm0xV016N3pLSUNMemI5QmJ1WXlVeEpBdFVvRlRoYWtvLXhja2k?oc=5", "source_name": "TradingView", "published_at": "2026-06-28T04:09:46+00:00", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Solid Biosciences Inc. \u2013 NASDAQ:SLDB", "summary": "The article focuses on the \"Price to earnings forward\" metric for Solid Biosciences Inc. (NASDAQ: SLDB). It appears to be a truncated financial data page from TradingView, displaying the company's ticker, market status, and a navigation bar. The content does not elaborate on the ", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:39:55", "published_display": "27 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLDB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Solid Biosciences Inc. (SLDB) stock, detailing analyst price targets, historical stock performance, and financial data. It includes information on current stock price, market capitalization, earnings per share, revenue, and upcoming earnings d", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:30", "published_display": "25 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc. Actuals & Estimates (NASDAQ:SLDB)", "summary": "This article provides an overview of Solid Biosciences Inc. (NASDAQ: SLDB) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts for SLDB, notes recent earnings performance, and confirms the company's next earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:30", "published_display": "25 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A SOLID BIOSCIENCES INC. For: 24 June By Investing.com", "summary": "This article announces the filing of Form 13D/A by SOLID BIOSCIENCES INC. on June 24th, as reported by Investing.com. It is a brief administrative notice regarding a regulatory filing related to the company. The text includes various market data and news unrelated to the main sub", "url": "https://ca.investing.com/news/stock-market-news/form-13da-solid-biosciences-inc-for-24-june-93CH-4706422", "source_name": "Investing.com Canada", "published_at": "2026-06-25T07:10:36", "published_display": "25 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital (NASDAQ: SLDB) boosts Solid Biosciences holding to 11.9% ownership", "summary": "RA Capital Management and its affiliates have increased their beneficial ownership in Solid Biosciences Inc. (NASDAQ: SLDB) to 11.9%, now holding 12,036,126 shares of common stock. This increase follows recent purchases in June 2026, including 338,100 shares in open-market trades", "url": "https://www.stocktitan.net/sec-filings/SLDB/schedule-13d-a-solid-biosciences-inc-amended-major-shareholder-report-ad62fb2a2a6a.html", "source_name": "Stock Titan", "published_at": "2026-06-24T23:09:16", "published_display": "24 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis", "summary": "Solid Biosciences Inc (SLDB) currently has a valuation score of 6.24, placing it in the bottom tier of the Biotechnology & Medical Research industry. Its P/E ratio stands at -4.33, reflecting a significant drop from its recent high. The company has not yet disclosed relevant data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sldb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T10:11:17", "published_display": "23 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Jumps As H.C. Wainwright Lifts Price Target", "summary": "Solid Biosciences (SLDB) saw its stock jump by 14.29% after H.C. Wainwright raised its price target from $20 to $25, reiterating a Buy rating due to encouraging updates on the SGT-212 gene therapy program for Friedreich's ataxia. Despite significant R&D spending and negative prof", "url": "https://www.timothysykes.com/news/solidbiosciencesinc-sldb-news-2026_06_21-2/", "source_name": "Timothy Sykes", "published_at": "2026-06-21T14:40:01", "published_display": "21 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?", "summary": "Solid Biosciences (NASDAQ:SLDB) has a cash runway of about 2.2 years based on its March 2026 cash reserves and annual cash burn of US$173 million, though its cash burn increased by 61% over the last year. Despite this, analysts expect the company to reach cashflow breakeven in fo", "url": "https://www.sahmcapital.com/news/content/is-solid-biosciences-nasdaqsldb-in-a-good-position-to-invest-in-growth-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-20T01:40:01", "published_display": "20 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solid-biosciences-nanomosaic-announce-co-110000541.html", "source_name": "PR Newswire", "published_at": "2026-06-02T11:00:00+00:00", "published_display": "02 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences to Participate at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solid-biosciences-participate-upcoming-investor-120000193.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNZmhfTm1KTFBKb05td2FuTXZXbHdDY1p6dC1pbEpMTlotT3hEVTFzd2kzQWREbnRrTkdsbVAweFRabUJnMjdCaDNhVDhBTmo0R3lVUEc3YkdTQlBKOTNBNkRVMmxNd195TDkwd1lWN1NQdmlCUHlCaDFkaERfRVFlaTJvcU16YUh0eG16ZjJ4VE1naHNJRmxyTmZub1NsMFpCYV9ObTN4TEk0SUs2MHVpQk5vVjl5a2JwYV9lYWRrRndVak1YckVyUTVhb0ZXb3RmOFRHMGJiNENROEVwbzMyOGMtdXc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRXRsY05VWUN4a0FqaThncC0tQXIzWV9VOFpIaHpMa2RqZUtkSTZxa2ZlazBiNTFNWVNUOEMzRFFNMnpENG1OWF9YQk5mVjNnMlJIOGZnY1VkaUZMU0pJVkU5bnd5dGQ3a3pmckNvY01JNUthUVVlLXl5ak5jX3ZCWTRWVXo2bGY3S2xNT1BoaElxRFA1SlFsOG5NZ3U3WkZVbW5J?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/news/wedbush-adjusts-price-target-solid-132616113.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:26:16+00:00", "published_display": "13 May 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/news/solid-biosciences-reports-first-quarter-200800497.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:08:00+00:00", "published_display": "12 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solid-biosciences-doses-first-participant-120000786.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T12:00:00+00:00", "published_display": "07 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQN3JCUkVnVTBTbnpvT0lwdWpfUFktaXh0TldOd2Jkb1A5U0JhV3AzMld5bm9Cemczd2lFZDlvcFJQWFBKTV9zdnVqd3ZJdU1wZ1EzR1ZwX0xsTmp2UmhHdERsNVhOa3h6NFVERU85VmlfLWgyZ3VwMHVOa0QteFQyNU9mYV9UN3ppUWRrY0MxZUY0aDA5VjcwbXFSeWZsbEdJellhaVV1MHpfZGZJb25PUmdRaUZVZm11ZkZ3WnRoaHo4TmJqN3RGVllQMkNPQmFHV2xtRl9kSWtpb2NkMG1fMkdxUHVqTmM?oc=5", "source_name": "TradingView", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Insiders Sold US$823k Of Shares Suggesting Hesitancy", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPTTczM3h2QzRacGJUWlNYOE93UlN1VWNDMnhIRTA1WXVtNHVfSHFHNjBsU0xtMnhLdEFITnNHZWJhY3BVSlBUX0MzZ3JxbE9fX2c2eXdTNXhZZlpZekN6bkNVOXJNbmlVUWVHZkdvWDBQMWl5OHpNaURzVTRtemJIb3EzdC1GbE41eTh0aWc0enRSdDViNll4WU1jSXNuNmRFTnVuSUlHSzF5QTNpa1J1Nw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Solid Biosciences (SLDB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1sY3prelA0eXp4SmViYlJTZDBSSmFpSkxlU09zV0hnaUFudmhib3ZaNnhxOGhocG1uNWx3Z1ZKb3VUUHZmaE94UDZfamN6RTlaUmZQRnVDUFBGbkZaVlBKVl9FWUE4MXFjVU9mOA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Solid Biosciences (SLDB) Proxy filing Summary", "summary": "Solid Biosciences (SLDB) has released its proxy filing summary, detailing proposals for its virtual annual meeting on June 10, 2026. Key items include the election of three Class II directors, ratification of an advisory appointment, approval of the external auditor, and an amend", "url": "https://quartr.com/events/solid-biosciences-inc-sldb-proxy-filing_FkM9LW2d", "source_name": "Quartr", "published_at": "2026-07-16T06:11:14", "published_display": "16 Jul 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences (SLDB) Registration filing Summary", "summary": "This document summarizes Solid Biosciences' (SLDB) registration filing from March 2026, detailing the company's focus on gene therapy for rare neuromuscular and cardiac diseases. It highlights a $240 million private placement, the registration of 42.78 million shares for resale, ", "url": "https://quartr.com/events/solid-biosciences-inc-sldb-registration-filing_FkM9LxPV", "source_name": "Quartr", "published_at": "2026-07-13T10:41:00", "published_display": "13 Jul 2026 10:41", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences (SLDB) AGM 2026 Summary", "summary": "This article summarizes Solid Biosciences' (SLDB) 2026 Annual General Meeting (AGM) held on June 12, 2026, as a virtual event. Key outcomes included the election of three Class II directors and the advisory ratification of a Class I director, with a quorum established at 86.57% o", "url": "https://quartr.com/events/solid-biosciences-inc-sldb-agm-2026_FkM9LnAx", "source_name": "Quartr", "published_at": "2026-07-13T01:11:28", "published_display": "13 Jul 2026 01:11", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors May Respond To Solid Biosciences (SLDB) Joining Multiple Russell Growth Indices", "summary": "Solid Biosciences Inc. (SLDB) was recently added to several Russell growth indices, including the Russell 2000, 2500, 3000, 3000E, Microcap, and Small Cap Comp Growth indices. This inclusion is expected to increase the company's visibility to institutional investors and index-tra", "url": "https://www.sahmcapital.com/news/content/how-investors-may-respond-to-solid-biosciences-sldb-joining-multiple-russell-growth-indices-2026-07-11", "source_name": "Sahm", "published_at": "2026-07-11T23:11:14", "published_display": "11 Jul 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Solid Biosciences (SLDB) Undervalued Following Its Russell Growth Index Additions?", "summary": "Solid Biosciences (SLDB) has been added to several Russell growth indices following a significant share price increase. A Discounted Cash Flow (DCF) model by Simply Wall St suggests the stock is undervalued with a fair value of $140.99 per share compared to its current price of $", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sldb/solid-biosciences/news/is-solid-biosciences-sldb-undervalued-following-its-russell/amp", "source_name": "Simply Wall Street", "published_at": "2026-07-08T09:10:56", "published_display": "08 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Solid Biosciences LLC For: 7 July By Investing.com", "summary": "This article reports on a Form 4 filing by Solid Biosciences LLC for July 7, 2026. Form 4 filings are used to disclose changes in beneficial ownership of securities by company insiders. The brief piece indicates that financial markets worldwide can access this information via Inv", "url": "https://ng.investing.com/news/stock-market-news/form-4-solid-biosciences-llc-for-7-july-93CH-2589650", "source_name": "Investing.com Nigeria", "published_at": "2026-07-07T21:10:56", "published_display": "07 Jul 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Director at Solid Biosciences (SLDB) converts 3,440 RSUs into shares", "summary": "Solid Biosciences Inc. director Ian F. Smith converted 3,440 Restricted Stock Units (RSUs) into common stock on July 2, 2026, at a price of $0.00 per share. This transaction increased his direct holdings to 138,145 shares of Common Stock, with an additional 6,880 RSUs remaining. ", "url": "https://www.stocktitan.net/sec-filings/SLDB/form-4-solid-biosciences-inc-insider-trading-activity-3e9b2deb6698.html", "source_name": "Stock Titan", "published_at": "2026-07-07T20:05:53", "published_display": "07 Jul 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences updates gene therapy pipeline as investors watch clinical strategy", "summary": "Solid Biosciences, a clinical-stage biotechnology company, is refining its gene therapy focus and clinical strategy for rare neuromuscular and cardiac diseases. The company, which is listed on Nasdaq, is centered on providing long-term treatment options for patients and relies on", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/solid-biosciences-updates-gene-therapy-pipeline-as-investors-watch/69715663", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:40:53", "published_display": "07 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Solid Biosciences' (SLDB) Russell Index Debut Hint at a Turning Point in Its Growth Story?", "summary": "Solid Biosciences Inc. (SLDB) was recently added to several Russell growth and small-cap indices, including the Russell 2000 Growth and Russell 3000 Growth. This inclusion is expected to increase institutional visibility and liquidity for the company's stock. While it could broad", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sldb/solid-biosciences/news/does-solid-biosciences-sldb-russell-index-debut-hint-at-a-tu", "source_name": "Simply Wall Street", "published_at": "2026-07-03T07:39:34", "published_display": "03 Jul 2026 07:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences: The Bull Case Is No Longer Just Duchenne", "summary": "Solid Biosciences (SLDB) is transitioning from a Duchenne gene therapy focus to a broader multi-asset rare disease platform, supported by its $380.7M cash position funding operations into 2028. The company's SGT-003 program shows promising Phase 1/2 data for Duchenne, and new pro", "url": "https://seekingalpha.com/article/4919335-solid-biosciences-stock-bull-case-no-longer-just-duchenne", "source_name": "Seeking Alpha", "published_at": "2026-07-02T11:40:10", "published_display": "02 Jul 2026 11:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences stock hits 52-week high at $10.44", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQbHdwempjYWpJNjBUUnJTYllUZmhkUU5tRlJoaTBaTjJNVWpFWTl0d2ZXSHR4dmtIVk9uWmJDQTZ3eTI4Y3d4NnM1a0dydTljR0Zad1lYVEZwdnZjdTR2eDZBZWliRHRjX3dPd3A2d3hEWHFtYUNXeUZiTWd2U0JscUIzbXR4Q05qaFBlcE5DTUdLOXdsbmgwRVNlRjFCT2s3WVN4NDJyNnI?oc=5", "source_name": "Investing.com", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Solid Biosciences' (SLDB) Russell Growth Index Debut Reveal a Shift in Its Investor Base?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPc2VCdXd5eW9lQjlydGNGeFpERjAzQ3BFbkVNdDBKaHE3eGdaUXlURVQ0SHlfVUF6enhHT0twTW9kNGRvemF3ZmUxcVVYQUUwUzFCWVZPY0ptNTJualhxMEVtdFZnWU5aVTRkbUZWTFRfSUFtcG9LVXFVdVFvcmFZbFdCY1VDS0JYalRNX2ZaeVRFSDlHcHZJaEZKNk9nUmM0ZkE?oc=5", "source_name": "Market source", "published_at": "2026-07-01T07:00:00+00:00", "published_display": "01 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc.(NasdaqGS: SLDB) added to Russell 2000 Growth Benchmark", "summary": "Solid Biosciences Inc. (NasdaqGS: SLDB), a life sciences company focused on genetic medicines for neuromuscular and cardiac diseases, has been included in the Russell 2000 Growth Benchmark. This addition follows its recent inclusion in the Russell 3000E Growth Benchmark and the S", "url": "https://www.marketscreener.com/news/solid-biosciences-inc-nasdaqgs-sldb-added-to-russell-2000-growth-benchmark-ce7f5fdede81f526", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T11:12:14", "published_display": "29 Jun 2026 11:12", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc.(NasdaqGS:SLDB) added to Russell Microcap Growth Benchmark Index", "summary": "Solid Biosciences Inc. (SLDB) has been added to the Russell Microcap Growth Benchmark Index, as reported on June 28, 2026. This inclusion highlights the company's progress and visibility within the biotechnology and medical research sector. Solid Biosciences specializes in develo", "url": "https://www.marketscreener.com/news/solid-biosciences-inc-nasdaqgs-sldb-added-to-russell-microcap-growth-benchmark-index-ce7f5fddd981f220", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T06:10:07", "published_display": "29 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Solid Biosciences Inc. \u2013 NASDAQ:SLDB", "summary": "This article provides financial information for Solid Biosciences Inc. (NASDAQ: SLDB), specifically focusing on its forward price-to-sales ratio. The content lists the company's financial overview within the context of the biotechnology sector.", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T10:40:54", "published_display": "28 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Solid Biosciences Inc. \u2013 NASDAQ:SLDB", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxNdTZWUEtYU3VIcHZOSWFRc3o1ZXpjVG9NdkkwbDVLaTFNQjhZcF9lWmt4UnVHSl8wREtwM3phYkcyTHlKeWp3dDdnOXRjQXk0QmlONjhOa29MdVMtSVB5R09aWkozdUNBZ25SWHpaaVZpRTZjQXRMWm0xV016N3pLSUNMemI5QmJ1WXlVeEpBdFVvRlRoYWtvLXhja2k?oc=5", "source_name": "TradingView", "published_at": "2026-06-28T04:09:46+00:00", "published_display": "28 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Solid Biosciences Inc. \u2013 NASDAQ:SLDB", "summary": "The article focuses on the \"Price to earnings forward\" metric for Solid Biosciences Inc. (NASDAQ: SLDB). It appears to be a truncated financial data page from TradingView, displaying the company's ticker, market status, and a navigation bar. The content does not elaborate on the ", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T23:39:55", "published_display": "27 Jun 2026 23:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SLDB Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Solid Biosciences Inc. (SLDB) stock, detailing analyst price targets, historical stock performance, and financial data. It includes information on current stock price, market capitalization, earnings per share, revenue, and upcoming earnings d", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T20:11:30", "published_display": "25 Jun 2026 20:11", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc. Actuals & Estimates (NASDAQ:SLDB)", "summary": "This article provides an overview of Solid Biosciences Inc. (NASDAQ: SLDB) stock, including its current price, market capitalization, and historical performance. It details analyst forecasts for SLDB, notes recent earnings performance, and confirms the company's next earnings rep", "url": "https://www.tradingview.com/symbols/NASDAQ-SLDB/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:11:30", "published_display": "25 Jun 2026 18:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 13D/A SOLID BIOSCIENCES INC. For: 24 June By Investing.com", "summary": "This article announces the filing of Form 13D/A by SOLID BIOSCIENCES INC. on June 24th, as reported by Investing.com. It is a brief administrative notice regarding a regulatory filing related to the company. The text includes various market data and news unrelated to the main sub", "url": "https://ca.investing.com/news/stock-market-news/form-13da-solid-biosciences-inc-for-24-june-93CH-4706422", "source_name": "Investing.com Canada", "published_at": "2026-06-25T07:10:36", "published_display": "25 Jun 2026 07:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "RA Capital (NASDAQ: SLDB) boosts Solid Biosciences holding to 11.9% ownership", "summary": "RA Capital Management and its affiliates have increased their beneficial ownership in Solid Biosciences Inc. (NASDAQ: SLDB) to 11.9%, now holding 12,036,126 shares of common stock. This increase follows recent purchases in June 2026, including 338,100 shares in open-market trades", "url": "https://www.stocktitan.net/sec-filings/SLDB/schedule-13d-a-solid-biosciences-inc-amended-major-shareholder-report-ad62fb2a2a6a.html", "source_name": "Stock Titan", "published_at": "2026-06-24T23:09:16", "published_display": "24 Jun 2026 23:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Inc (SLDB) Valuation: PE, PB & Fair Value Analysis", "summary": "Solid Biosciences Inc (SLDB) currently has a valuation score of 6.24, placing it in the bottom tier of the Biotechnology & Medical Research industry. Its P/E ratio stands at -4.33, reflecting a significant drop from its recent high. The company has not yet disclosed relevant data", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-sldb/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-23T10:11:17", "published_display": "23 Jun 2026 10:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Jumps As H.C. Wainwright Lifts Price Target", "summary": "Solid Biosciences (SLDB) saw its stock jump by 14.29% after H.C. Wainwright raised its price target from $20 to $25, reiterating a Buy rating due to encouraging updates on the SGT-212 gene therapy program for Friedreich's ataxia. Despite significant R&D spending and negative prof", "url": "https://www.timothysykes.com/news/solidbiosciencesinc-sldb-news-2026_06_21-2/", "source_name": "Timothy Sykes", "published_at": "2026-06-21T14:40:01", "published_display": "21 Jun 2026 14:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?", "summary": "Solid Biosciences (NASDAQ:SLDB) has a cash runway of about 2.2 years based on its March 2026 cash reserves and annual cash burn of US$173 million, though its cash burn increased by 61% over the last year. Despite this, analysts expect the company to reach cashflow breakeven in fo", "url": "https://www.sahmcapital.com/news/content/is-solid-biosciences-nasdaqsldb-in-a-good-position-to-invest-in-growth-2026-06-19", "source_name": "Sahm", "published_at": "2026-06-20T01:40:01", "published_display": "20 Jun 2026 01:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solid-biosciences-nanomosaic-announce-co-110000541.html", "source_name": "PR Newswire", "published_at": "2026-06-02T11:00:00+00:00", "published_display": "02 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences to Participate at Upcoming Investor Conferences", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solid-biosciences-participate-upcoming-investor-120000193.html", "source_name": "GlobeNewswire", "published_at": "2026-06-01T12:00:00+00:00", "published_display": "01 Jun 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxNZmhfTm1KTFBKb05td2FuTXZXbHdDY1p6dC1pbEpMTlotT3hEVTFzd2kzQWREbnRrTkdsbVAweFRabUJnMjdCaDNhVDhBTmo0R3lVUEc3YkdTQlBKOTNBNkRVMmxNd195TDkwd1lWN1NQdmlCUHlCaDFkaERfRVFlaTJvcU16YUh0eG16ZjJ4VE1naHNJRmxyTmZub1NsMFpCYV9ObTN4TEk0SUs2MHVpQk5vVjl5a2JwYV9lYWRrRndVak1YckVyUTVhb0ZXb3RmOFRHMGJiNENROEVwbzMyOGMtdXc?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Where Will Solid Biosciences Inc (SLDB) Stock Be in the Next 12 Months?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPRXRsY05VWUN4a0FqaThncC0tQXIzWV9VOFpIaHpMa2RqZUtkSTZxa2ZlazBiNTFNWVNUOEMzRFFNMnpENG1OWF9YQk5mVjNnMlJIOGZnY1VkaUZMU0pJVkU5bnd5dGQ3a3pmckNvY01JNUthUVVlLXl5ak5jX3ZCWTRWVXo2bGY3S2xNT1BoaElxRFA1SlFsOG5NZ3U3WkZVbW5J?oc=5", "source_name": "Market source", "published_at": "2026-05-20T07:00:00+00:00", "published_display": "20 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wedbush Adjusts Price Target on Solid Biosciences to $16 From $17, Maintains Outperform Rating", "summary": "", "url": "https://finance.yahoo.com/news/wedbush-adjusts-price-target-solid-132616113.html", "source_name": "MT Newswires", "published_at": "2026-05-13T13:26:16+00:00", "published_display": "13 May 2026 13:26", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates", "summary": "", "url": "https://finance.yahoo.com/news/solid-biosciences-reports-first-quarter-200800497.html", "source_name": "GlobeNewswire", "published_at": "2026-05-12T20:08:00+00:00", "published_display": "12 May 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Doses First Participant in Phase 3 IMPACT DUCHENNE Clinical Trial Evaluating SGT-003 in Duchenne Muscular Dystrophy", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/solid-biosciences-doses-first-participant-120000786.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T12:00:00+00:00", "published_display": "07 May 2026 12:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Raises $240 Million in Private Placement of Stock and Pre-Funded Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQN3JCUkVnVTBTbnpvT0lwdWpfUFktaXh0TldOd2Jkb1A5U0JhV3AzMld5bm9Cemczd2lFZDlvcFJQWFBKTV9zdnVqd3ZJdU1wZ1EzR1ZwX0xsTmp2UmhHdERsNVhOa3h6NFVERU85VmlfLWgyZ3VwMHVOa0QteFQyNU9mYV9UN3ppUWRrY0MxZUY0aDA5VjcwbXFSeWZsbEdJellhaVV1MHpfZGZJb25PUmdRaUZVZm11ZkZ3WnRoaHo4TmJqN3RGVllQMkNPQmFHV2xtRl9kSWtpb2NkMG1fMkdxUHVqTmM?oc=5", "source_name": "TradingView", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences Insiders Sold US$823k Of Shares Suggesting Hesitancy", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxPWmN5bGpSRS1neFNDVmR5cDFFTjdWRlJSYXJWaVpDTWRORzUwa29iOGFMemJjYlROWURoeXN2UUlrUGF1cldiU2N1ZUpQai1Vd3UzanJ0TjZSTXlPSjA4WlVuX0c3dnB2d19KdUlQalRxa2x0VDJ4SWxvWFh3Z19zWFVRUFBZSF9wOWxYYjEtNWQ4ckZfRzlrOXBPOThvUGJnaURrT3FtMUxFWTc5U0JyOHoxeHdfblhBODNnR0VNeVJ4VDM1U3RlN0hXX3FGNXFVaC1aMkxmQ1FuYmRHci1tdkhFbFjSAeoBQVVfeXFMT1lMc0RDQ0kzMUg3N0RhbnN3dEdIenR2UHpqdW1UQVF5VDhUUzQzdndTd3hKaEdKT013UVlOakF5bXdqbUFuQ2VBamlPVXNqaW9wSGRhMm1ZQkgwU0cxbGN4dHVsS3FMd2VpdTFWYUFTVTRwdV9qTUtNeDJqY0pVb1IzYjk4RVg2WmF4RzVrOGxjZGdNV0NWbzBtenJ0b3QzYzRnU0JHSTRieEtnOUhRelJrYjh4ekJtdERncjY4UFpLZzNXMVVENE40MzhjOV9iU3ZCSnVKZFZMOXkwWlN5M1pZcFlUY01MeVlR?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxPTTczM3h2QzRacGJUWlNYOE93UlN1VWNDMnhIRTA1WXVtNHVfSHFHNjBsU0xtMnhLdEFITnNHZWJhY3BVSlBUX0MzZ3JxbE9fX2c2eXdTNXhZZlpZekN6bkNVOXJNbmlVUWVHZkdvWDBQMWl5OHpNaURzVTRtemJIb3EzdC1GbE41eTh0aWc0enRSdDViNll4WU1jSXNuNmRFTnVuSUlHSzF5QTNpa1J1Nw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-02-09T08:00:00+00:00", "published_display": "09 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Solid Biosciences (SLDB)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTE1sY3prelA0eXp4SmViYlJTZDBSSmFpSkxlU09zV0hnaUFudmhib3ZaNnhxOGhocG1uNWx3Z1ZKb3VUUHZmaE94UDZfamN6RTlaUmZQRnVDUFBGbkZaVlBKVl9FWUE4MXFjVU9mOA?oc=5", "source_name": "Zacks Investment Research", "published_at": "2026-01-16T08:00:00+00:00", "published_display": "16 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 81, "total_relevant": 44, "sentiment_summary": {"positive": 17, "negative": 1, "neutral": 26, "score": 58, "total": 44, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 13.35, "count": 23}, {"event": "earnings", "label": "Earnings", "weight": 5.91, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.55, "count": 4}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}], "positive_events": 17, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 10.42, "latest_week": "2026-07-10", "one_week_move": -3.9, "four_week_move": 45.9, "twelve_week_move": 20.7, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.877389, "market_dynamics_buy_signal": false, "relative_strength": 37.841865, "fair_value_gap": 71.4, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 45.5275, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.9% over one week, +45.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 7}, {"label": "GlobeNewswire", "count": 4}, {"label": "Quartr", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Sahm", "count": 2}, {"label": "Simply Wall Street", "count": 2}, {"label": "Stock Titan", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 23}, {"label": "Earnings", "count": 13}, {"label": "Balance sheet", "count": 4}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.9% over one week, +45.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Solid Biosciences (SLDB) Proxy filing Summary"}], "updated_at": "2026-07-17T21:25:30.418183+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}